Clinical Trial Update: A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A phase 2 trial of Ompenaclid with FOLFIRI plus bevacizumab in advanced/metastatic colorectal cancer was terminated. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• Ompenaclid (Ompenaclid)

Snippet

Sponsor: Inspirna, Inc. | Conditions: Colorectal Cancer, Metastatic Colon Cancer | Phase 2 | Status: TERMINATED | Results posted: 2026-02-20